A pill who would allow us to lose weight and stop smoking, you dream ... And this dream should become reality next year. However, that's not all; this drug could also be extremely effective in treating diabetes. Focus on a molecule that has not finished talking to her.
Acomplia ®, since it is the name of this drug is the first born, and only representative to date, a new class of drugs called selective blockers of cannabinoid receptor 1. Clearly, this substance is capable of blocking a receptor that stimulates the appetite and cravings. This molecule, called rimonabant, may revolutionize the treatment of obesity and smoking cessation. Another string to its bow, rimonabant also intervene on many risk factors associated with diabetes.
Towards a new diabetes treatment
The result of the RIO-Diabetes was eagerly awaited by many doctors. And for a good reason, more than 190 million people worldwide currently suffer from diabetes. The study, published June 12, 2005, shows that Acomplia ® could revolutionize the treatment of this disease with dramatic consequences. During one year, 1000 patients with type two diabetes was given a daily dose of 20 mg of rimonabant. A result: There was a significant decrease in glycated hemoglobin, a major parameter monitoring of blood sugar, and the improvement of hypertension and lipid levels.
Another important point, this drug reduces abdominal obesity in patients already treated for diabetes. Good news when we know that stomachic obesity, which reflects visceral adiposity, predicts the occurrence of myocardial infarction ... to Professor Michael D. Jensen "weight loss reported with rimonabant in diabetic patients is potentially very interesting. Indeed, the current anti-diabetic improves glycemia but often accompanied by the weight gains. This weight gain may itself even diminish the benefits of treatment and downgrade the overall improvement of the risk factors associated cardio metabolic "
Weight loss of the patient group treated with the drug was 5.3 kg against 1.4 kg for placebo patients. Side waist, patients on rimonabant lost 5.2 cm against 1.9.
Haro on cardiovascular risk
The beneficial effects on cholesterol and triglycerides are not to be ignored because they help reduce cardiovascular risks associated with diabetes, obesity and pathology of this increasingly common so-called " metabolic syndrome " , which triples the likelihood of a stroke.
It is important to note that this study was conducted with the usual rigor of clinical studies. Several research centers were involved, patients who took the drug were randomly selected and neither the caregiver, nor the patient knew the true nature of the received product (drug or placebo). The study included overweight patients with type two diabetes who had been treated with an oral antidiabetic such as sulfonylureas ( DAONIL ®, DIAMICRON ®, OZIDIA ® ®) or metformin ( Glucophage ®, STAGID ®.).
A deadly epidemic
The future finally announces it brighter for people with diabetes? It was time for this disease has become a scourge to the point that today we speak of an epidemic; 333 million people will be diabetic in less than 20 years. All these patients are exposed not only to major cardiovascular risk but also to kidney disease; arteritis of the lower limbs, amputations, blindness ... This new drug is expected to significantly improve their prognosis but also their quality of life.
Notice: Want to know when we update our site? Enter your email address below and be notified by mail every time we update our site